Pay in 4 interest-free payments of $6.72 Learn more
Ships within 48 hours · Estimated delivery Aug 17 - Aug 22
Patients who had touched Semaglutide 2.4 mg post the run-in periods were randomized to continue with the treatment of Semaglutide or continue with the placebo for 48 weeks
Solutions include increasing the dose (raising the entire curve including the trough), splitting the dose into twice-weekly injections (reducing the trough depth while maintaining the same total weekly dose), or switching to a medication with a longer half-life (semaglutide troughs are shallower than tirzepatide troughs due to its longer half-life)
It is still too early to gauge the prescription volume that Humana is processing through the Bridge Program, but GLP-1 Bridge Program claims volume is expected to grow as more patients become aware of the program
Buyers should consider requesting and reviewing the following to avoid successor liability: Vendor qualification files Sourcing records Compounding agreements Product labels and invoices Training records Storage and temperature logs All marketing materials referencing GLP-1 products Any history of state or federal regulator inquiries Conclusion The enforcement wave surrounding GLP-1 drugs reflects an emerging regulatory reality
